ArticleFrontiers in endocrinology2025
Aqueous-humor biomarkers and real-world efficacy of conbercept for diabetic macular edema: a prospective study in elderly patients.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate real-world efficacy of conbercept and the predictive value of aqueous-humor biomarkers in elderly diabetic macular edema (DME). Methods: In this single-arm, prospective study, 150 patients ≥ 65 years received three monthly conbercept injections followed by pro-re-nata dosing over 6 months. Baseline vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) levels were quantified from aqueous humor; best-corrected visual acuity (BCVA) and central subfield thickness (CST) were monitored. Mixed-effects modelling and receiver-operating-characteristic (ROC) analysis explored associations between biomarkers and outcomes. Results: Mean BCVA improved by approximately nine ETDRS letters, and CST declined by about 85 µm at Month 6. Higher baseline VEGF and IL-6 were associated with greater CST reduction and moderately increased odds of a ≥ 15-letter gain; VEGF showed fair discriminative ability (AUC=0.74). Treatment was well-tolerated, with no unexpected ocular or systemic adverse events. Conclusion: Conbercept produced meaningful anatomical and functional benefits in an elderly DME cohort. Baseline aqueous VEGF and IL-6, while not definitive stand-alone tests, may help identify eyes likely to achieve pronounced anatomical improvement and warrant further investigation as components of a multi-marker predictive panel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.